Advertisement

Related Videos

R. Donald Harvey, PharmD, BCOP, FCCP, FHOPA, on Alternative Dispensing Strategies

Javid J. Moslehi, MD, on Cardiovascular and Thrombotic Considerations of Kinase Inhibitors: The Case of BTK Inhibitors

The Interventional Pharmacoeconomic Toolbox Panel Discussion

Clifford A. Hudis, MD: Are Cancer Drug Prices in the U.S. the Problem or the Symptom?

Deborah Collyar: What's In It for Patients?

Advertisement

Advertisement




May
08
Today In Oncology
Curing Most Leukemias on the Horizon: A 5-Decade MD Anderson Perspective on Leukemia Research
Long-Term Outcomes With Maintenance Rucaparib in Advanced Pancreatic Cancer With BRCA or PALB2 Pathogenic Variants
Tiragolumab Plus Atezolizumab and Chemotherapy in Advanced Nonsquamous NSCLC
Appendiceal Cancer: Serum Tumor Marker Levels May Guide Treatment in Patients Undergoing CRS
High YAP1 Expression Leads to Chemotherapy Resistance Relapse in Treated SCLC
View More 
Advertisement
© 2026 HSP News Service, L.L.C.
Conexiant Oncology Logo